Arcturus Therapeutics
ARCT
135 hedge funds and large institutions have $865M invested in Arcturus Therapeutics in 2020 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 54 increasing their positions, 33 reducing their positions, and 32 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 33
28% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 32
26% more call options, than puts
Call options by funds: $46.9M | Put options by funds: $37.1M
10% more capital invested
Capital invested by funds: $783M → $865M (+$81.7M)
6% more funds holding
Funds holding: 127 → 135 (+8)
2.24% more ownership
Funds ownership: 74.68% → 76.92% (+2.2%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$141M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$99.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$48.7M |
| 4 |
O
OrbiMed
New York
|
+$44.8M |
| 5 |
BlackRock
New York
|
+$42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
-$68.4M |
| 2 |
State Street
Boston,
Massachusetts
|
-$37.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$30M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$20.7M |
| 5 |
EARNEST Partners
Atlanta,
Georgia
|
-$20.6M |
ARCT Hedge Fund Activity: Q4 2020 in Review
135 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q4 2020, worth a combined $865M — up 10% from $783M a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new ARCT positions and 32 closed out — a net gain of 9 holders — while 54 added to existing stakes and 33 trimmed.
The largest buyer was Federated Hermes, adding an estimated $141M. The largest seller was HealthCor Management, exiting entirely with an estimated $68.4M sold.
- 135 institutional investors held Arcturus Therapeutics (ARCT) as of Q4 2020, up from 127 in Q3 2020.
- Funds reported $865M of Arcturus Therapeutics stock for Q4 2020, up 10% quarter-over-quarter.
- 41 funds opened new Arcturus Therapeutics positions in Q4 2020 and 32 closed out, a net change of +9 holders.
- The largest Arcturus Therapeutics buyer in Q4 2020 was Federated Hermes, an estimated $141M added.
- The largest Arcturus Therapeutics seller in Q4 2020 was HealthCor Management, an estimated $68.4M sold.
Based on aggregated 13F filings for Q4 2020.